106149-34-2

Upstream product

• 1450-72-2 5-methyl-2-hydroxyacetophenone 
• 140-39-6 1-acetoxy-4-methylbenzene 
• 106-44-5 p-cresol 
• 122-04-3 4-nitro-benzoyl chloride 
• 36695-11-1 1-[2-(4-nitrobenzoyloxy)-5-methylphenyl]-ethanone 

Downstream Products

• 1350428-76-0 C₂₀H₂₄N₄O 
• 763133-41-1 4-methyl-2-(5-(4-nitrophenyl)-1H-pyrazol-3-yl)phenol 
• 1350428-75-9 4-methyl-2-(5-(4-aminophenyl)-1H-pyrazol-3-yl)phenol 
• 1350428-74-8 4-methyl-2-(5-(4-azidophenyl)-1H-pyrazol-3-yl)phenol 
• 1343513-03-0 C₁₈H₁₆N₂O₄ 
• 1343513-04-1 6-((1H-imidazol-1-yl)methyl)-2-(4-nitrophenyl)-4H-chromen-4-one 
• 1343513-05-2 N,N-diethyl-N-((2-(4-nitrophenyl)-4-oxo-4H-chromen-6-yl)methyl)ethanaminium 
• 1343513-16-5 2-(4-aminophenyl)-6-((diethylamino)methyl)-4H-chromen-4-one 
• 1343512-99-1 6-((diethylamino)methyl)-2-(4-nitrophenyl)-4H-chromen-4-one 
• 1343513-00-7 2-(4-nitrophenyl)-6-(piperidin-1-ylmethyl)-4H-chromen-4-one 
• 1343513-51-8 C₁₆H₁₀BrNO₄ 
• 1343513-01-8 6-((4-methylpiperazin-1-yl)methyl)-2-(4-nitrophenyl)-4H-chromen-4-one 
• 1343513-02-9 6-(morpholin-4-ylmethyl)-2-(4-nitrophenyl)-4H-chromen-4-one 
• 250262-43-2 6-methyl-2-(4-nitrophenyl)-4H-chromen-4-one 

Relevant academic research and scientific papers

Investigation on the substitution effects of the flavonoids as potent anticancer agents: A structure-activity relationships study

Three series of flavonoid analogues substituted with different aminomethyl substitutions at C-6, C-7, and C-8 were designed and synthesized for the structure-activity relationship studies as potent anticancer agents. The prepared analogues were evaluated for their in vitro inhibitory activity against the growth of the hepatic cancer cell lines HepG2 and SMMC-7721. Structure-activity relationships indicated that not only the compounds with amino methyl groups were more active than those without the groups in the same series but also the compounds substituted by aminomethyl groups at position C-8 were more active than those at positions C-6 and C-7.

Synthesis and properties of molecular probes for the rescue site on mutant cystic fibrosis transmembrane conductance regulator

Cystic fibrosis is a genetic disease caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In vitro experiments have demonstrated that 4-methyl-2-(5-phenyl-1H-pyrazol-3-yl)phenol (VRT-532, 1) is able t

Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABA(A) receptor complex

The affinities for the benzodiazepine binding site of the GABA(A) receptor of 21 flavonoids have been studied using [3H]flumazenil binding to rat cortical membranes in vitro. We show that flavonoids with high affinity for the benzodiazepine receptor in vitro spanning the whole efficacy range from agonists (1q) to inverse agonists (1l) can be synthesized. The receptor binding properties of the flavonoids studied can successfully be rationalized in terms of a comprehensive pharmacophore model recently developed by cook and co-workers (Drug Des. Dev. 1995, 12, 193-248), supporting the validity of this model. However, in contrast to the requirement by the model that an interaction with the hydrogen bond-accepting site A2 is necessary for compounds to display inverse agonistic activity, 6-methyl-3'-nitroflavone (1l), which cannot engage in such an interaction, nevertheless displays inverse agonism. The analysis of the binding affinities of 3'- and 4'- substituted flavones in terms of the pharmacophore model has yielded new information for the further development of the pharmacophore model.